CNTB

Connect Biopharma Holdings Limited (NASDAQ:CNTB) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Taicang, China. The company went public in March 2021 and focuses on discovering and developing immune modulators for treating serious autoimmune diseases and inflammatory conditions. Connect Biopharma operates in the highly specialized biotechnology sector, where companies typically spend years and hundreds of millions of dollars developing drug candidates through rigorous clinical trials before potentially bringing treatments to market.